Tagged with Venture Capital

Hong Kong As managing director of the CR-CP Life Science Fund, whose shareholders, CR Group and CP Group, are on the Fortune Global 500 List, Da Liu leads investments in life sciences companies globally, especially those in emerging sectors such as RNA therapeutics and cancer screening. In conversation with PharmaBoardroom, Liu discusses…

Global Based on analysis from Crunchbase, read on for 2021’s largest VC investments into the biotech industry (which topped USD 65 billion last year) and 2021’s busiest biotech lead investors overall.   Made with Visme Infographic Maker   Made with Visme Infographic Maker

UK Oxford Nanopore hogged the UK biotech headlines in 2021, raising GBP 195 million in a single venture capital round – the year’s largest – and scoring a GBP 350 million listing on the London Stock Exchange, according to new data from the UK BioIndustry Association (BIA) and Clarivate. See below…

Japan Prof. Yoshiaki Tsukamoto, executive director of the Japan Bioindustry Association (JBA), talked exclusively to PharmaBoardroom at the BIO 2017 conference in San Diego on the role of his organization within Japan and his mission to instill a start-up culture within the Japanese biopharmaceutical industry. “[My mission is] urging universities, biotech start-ups…

Mexico Hernán Fernández, Managing Partner at Angel Ventures, showcases the crucial role of private investments to enhance the national healthcare system as well as explains his action plan to raise the funds for the first regional venture capital fund in Latin America. Mr. Fernández, what are the points that triggered you…

Life Sciences The funding of Canada’s biotech industry has changed drastically in recent years. Peter Van Der Velden of Lumira Capital discusses those changes and how his venture capital business is adapting to this evolving environment. Lumira has been involved with numerous acquisitions over the years. Could you highlight a couple of…

Biosimilars Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars will be able to overcome the initial barriers, and where he sees EiGenix in the next several years. What has…

R&D Whaijen Soo, Managing Director of Supra Integration and Incubation Center (Si2C) speaks about Taiwan’s biotech industry, emphasizing the need for risk tolerance and understanding investing rationale in propelling Taiwan’s industry to the global forefront.  Taiwan Supra Integration and Incubation Center (Si2C), was launched in November 2011 with the intention of…

Biosimilars Audrey Tseng, Deputy Chairman of PwC Taiwan with PwC Partners Lily Wong and Andy Chang, delve into factors behind the booming pharma and biotech industry in Taiwan, how to prevent a bubble burst, and the crucial next steps in maintaining the momentum to continue growth within the industry. Please start…

OtoSim Inc. OtoSim’s CEO Andy Sinclair discusses the current issues surrounding otoscopy diagnosis and the potential of the company’s groundbreaking simulation technology. What was your motivation for getting involved with OtoSim Inc. originally? OtoSim’s inventors submitted an invention disclosure via the Hospital for Sick Children (SickKids) to MaRS Innovation, where I was…

Ernst & Young LLP   Mario Piccinin and Lara Iob of EY Canada discuss some of the key trends of the country’s biotech industry and the affiliate’s dedication to helping clients navigate the SR&ED tax credit process available in Canada.   What do you see as the biggest challenges of life sciences clients in…

Financial Management YFY Biotech Management Company has not always been involved in the biotech sector. How has it evolved over the years? Yuen Foong Yu Group originally began as a paper mill company, which grew alongside Taiwan as the country moved from agriculture to industry. In moving away from its traditional business…